ISLR and pancreatic neoplasm: Moreover, Meflin KO mice exhibited a significant progression of pancreatic cancer when crossed with an autochthonous pancreatic cancer mouse model, indicating that Meflin+ CAFs retard cancer progression and are different from conventional cancer-promoting CAFs32.